Indatuximab ravtansine (BT062), an anti-CD138 monoclonal antibody conjugated with drug maytansinoid 4 (DM4), a cytotoxic maytansinoid derivative [113] has been shown to possess a favorable safety profile, with nausea, anemia, diarrhea, and fatigue as the most common adverse events in a dose-escalating phase 1 trial of 29 patients with relapsed and/or refractory MM [102]. The gene discussed is SDC1; the disease is Miyoshi myopathy.